Margaret R. Fleetwood, Ph.D.

Margaret R. Fleetwood, Ph.D.


Margaret R. Fleetwood is an associate with McDonnell Boehnen Hulbert & Berghoff LLP. Dr. Fleetwood concentrates her practice on patent prosecution as well as providing patentability and infringement analyses in the biotechnology and pharmaceuticals area.

Prior to joining MBHB, Dr. Fleetwood spent more than five years in technology transfer, serving as Manager of Technology Commercialization at the Polsky Center for Entrepreneurship and Innovation at the University of Chicago. In this role, she was responsible for strategic management and commercial advancement of portfolios for more than 30 commercially active faculty members. Her activities included evaluating new disclosures, initiating and overseeing patent prosecution, marketing, negotiating license terms for intellectual and tangible property, and drafting and finalizing a variety of contracts, as well as formalizing and maintaining license relationships. She also worked with both private and U.S. governmental agencies, such as the NIH, to secure rights to advance technologies through licensing programs and served as the Polsky Center’s liaison to the University’s conflict of interest committee. In addition to her work at University of Chicago, she has consulted at the Innovation and New Ventures Office (INVO) at Northwestern University, where she composed marketing abstracts for more than 25 University inventions in various technical fields.

During her academic tenure at the University of Pennsylvania Perelman School of Medicine, she worked as a Fellow at the Center for Technology Transfer (now part of the Penn Center for Innovation) where she evaluated University technologies from the life and physical sciences for purposes of patentability and marketability. Dr. Fleetwood also served as Director of the Intellectual Property Division of Penn Biotech Group, a Wharton Business School initiative that pairs local businesses with student teams for project work. In that role, she led teams in analyzing prior art on behalf of two biotechnology startup initiatives.